Miconazole dosage

Cavrini et al. [32] reported the development of a colorimetric method for the determination of miconazole nitrate in pharmaceutical preparation. The method is based on the formation of a yellow complex between the drug and bromocresol green. The absorption peak of this complex, extracted by chloroform over the pH 2—4 range, was at 424 nm, and linear response was obtained from 3—13 pg/mL. The molar absorptivity of the complex in chloroform was 1.845 x 104. This procedure is suitable for the analysis of miconazole nitrate in commercial dosage forms. 

Piel et al. compared the intravenous pharmacokinetics of miconazole in sheep after its administration in a polyoxyl-35 castor oil/lactic acid mixture, a 100 pM hydroxylpropyl-/l-cyclodextrin-50 pM lactic acid solution, and a 50 pM sulfobutyl ether (SBE7)-/i-cyclodextrin 50 pM lactic acid solution. Intravenous administration of 4 mg/kg of miconazole was completed within 5 min [108]. There were no differences of the miconazole blood plasma concentration versus time for the three dosage forms. The half-life of distribution was <2.4 min. Both hydroxylpropyl-/ -... 

Miconazole (2%, 4% vaginal cream 100 mg, 200 mg vaginal suppositories) see comments for dosage Monistat-7, Monistat-3 Insert one applicatorful intravaginally at bedtime for 7 consecutive days (2%) or 3 consecutive days (4%). Alternatively insert one... 

In the 1980s, Machida and Nagai evaluated spray dosage forms based on hydroxypropyl cellulose (HPC) for the delivery of beclomethasone to treat recurrent and multiple apthae. Previously a double-layered tablet of HPC and Carbopol 934P was introduced in the market for the treatment of apthous stomatitis. " Bouckaert, Lefebvre, and Remon " tested buccal tablets of miconazole based on modified starch-polyacrylic acid mixtures. Although these tablets showed different mucoadhesion properties in vitro, no significant differences in the salivary content of miconazole could be observed in human volunteers. 

Miconazole nitrute is supplied in a variety of dosage fonns (cream, lotion, powder, and spray) for the treatment of tinea infections and cuiiineous candidiasis. Vaginal creams and. suppositories are also available for the treatment of vaginal candidiasis. A conceiiiraiion of 2% of the salt is u.sed in moii topical preparations. 

Econazole. Econazole and isoconazole are structurally very similar to miconazole they differ only in the pattern of chlorine substitution on the terminal phenyl ring. Chemically, econazole (Fig. 2, 7b) is closely related to miconazole. The clinical indications are almost identical. Econazole [27220-47-9] is available as a vaginal cream and ovule containing respectively 1% and 150 mg econazole nitrate. For mycoses of the skin, several forms are available including cream, spray-powder, spray-solution, and lotion. All these formulations contain 1% econazole nitrate [68797-31-9]. The dosages are practically identical to those of miconazole. 

The interaction between miconazole and the sulphonylureas is established and clinically important, but of uncertain incidence. Concurrent use need not be avoided but it should be monitored and the dosage of the sulphony-lurea reduced if necessary. Patients should be warned. Information about other sulphonylureas not cited is lacking but it seems possible that they may interact similarly with miconazole. 

An example is a mucoadhesive tablet with miconazole. With this dosage form higher saliva concentrations are obtained compared to an oral gel, whilst no miconazole is detectable in blood plasma [9]. Other examples are buccal films, in use for the treatment of herpes labialis [10]. 

---